Market revenue in 2022 | USD 95.5 million |
Market revenue in 2030 | USD 157.6 million |
Growth rate | 6.5% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 55.71% in 2022. Horizon Databook has segmented the Argentina hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Rapidly aging women population and extensive R&D for hormonal therapy medications to treat symptoms o f menopause are among factors driving market growth over the forecast period. Hormonal therapy medications include progesterone, estrogen, medroxyprogesterone acetate, and a combination drug of estrogen & progesterone to lower the chances of disease related to hormones.
Currently, Activelle, Angeliq, Mesigyna, Kliogest, Utrogestan, Trisequens, Evorel Conti, Estragest TTS, Evorel, Ginediol, Progesterone Asofarma, and Equifem are some of the medicines used as hormonal replacement therapy in Argentina.
Progesterone Asofarma is composed of progesterone hormone, which is indicated for hormone replacement therapy, menopause, and perimenopause patients. Furthermore, Argentina is home to one o f Latin America's largest older populations. Argentina's population is aging as a result of declining fertility and mortality rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Argentina hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account